Gland Pharma Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Gland Pharma ha un patrimonio netto totale di ₹87.9B e un debito totale di ₹2.8B, che porta il suo rapporto debito/patrimonio netto a 3.2%. Le sue attività totali e le sue passività totali sono rispettivamente ₹108.7B e ₹20.8B. L'EBIT di Gland Pharma è ₹8.9B rendendo il suo rapporto di copertura degli interessi -7. Ha liquidità e investimenti a breve termine pari a ₹28.2B.

Informazioni chiave

3.2%

Rapporto debito/patrimonio netto

₹2.79b

Debito

Indice di copertura degli interessi	-7x
Contanti	₹28.20b
Patrimonio netto	₹87.88b
Totale passività	₹20.79b
Totale attività	₹108.67b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Gland Pharma Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Nov 07

Gland Pharma Limited (NSE:GLAND) Shares Could Be 23% Above Their Intrinsic Value Estimate

Oct 26

Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet

Oct 01

Investors Still Waiting For A Pull Back In Gland Pharma Limited (NSE:GLAND)

Sep 05

Gland Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 09

Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?

Jun 22

Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts

May 25

Is Gland Pharma (NSE:GLAND) A Risky Investment?

Mar 19

Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion

Feb 16

Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher

May 20

Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 07

Analysts Just Slashed Their Gland Pharma Limited (NSE:GLAND) EPS Numbers

Jul 22

Does This Valuation Of Gland Pharma Limited (NSE:GLAND) Imply Investors Are Overpaying?

Jul 14

Is Now The Time To Put Gland Pharma (NSE:GLAND) On Your Watchlist?

Feb 08

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ₹64.0B ) di GLAND superano le sue passività a breve termine ( ₹15.4B ).

Passività a lungo termine: Le attività a breve termine di GLAND ( ₹64.0B ) superano le sue passività a lungo termine ( ₹5.4B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: GLAND ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di GLAND è aumentato da 0.2% a 3.2% negli ultimi 5 anni.

Copertura del debito: Il debito di GLAND è ben coperto dal flusso di cassa operativo ( 437.2% ).

Copertura degli interessi: GLAND matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.

Gland Pharma Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet

Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?

Is Gland Pharma (NSE:GLAND) A Risky Investment?

Recent updates

Gland Pharma Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Gland Pharma Limited (NSE:GLAND) Shares Could Be 23% Above Their Intrinsic Value Estimate

Gland Pharma Limited Announces Chief Executive Officer Changes, Effective from January 15, 2025

Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet

Insufficient new directors

Gland Pharma Limited Announces Executive Changes

Investors Still Waiting For A Pull Back In Gland Pharma Limited (NSE:GLAND)

Gland Pharma Limited Announces Board Changes

Consensus EPS estimates fall by 16%

Gland Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Gland Pharma Limited to Report Q4, 2025 Results on May 20, 2025

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Gland Pharma Receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution

Gland Pharma Limited to Report Q1, 2025 Results on Aug 06, 2024

Insider recently sold ₹24m worth of stock

Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?

Fosun Pharma Industrial Reportedly to Pare 5% Stake in Gland Pharma for $172 Million

Head of Quality recently sold ₹8.3m worth of stock

Insider recently sold ₹9.2m worth of stock

Gland Pharma Limited Announces Management Changes

Insufficient new directors

Gland Pharma Limited Announces Resignation of C.S. Venkatesan as Sr. Vice President (R&D) and SMP, Effective June 30, 2024 and July 1, 2024 Respectively

Consensus EPS estimates fall by 14%, revenue upgraded

Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts

Gland Pharma Limited, Annual General Meeting, Aug 30, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q4, 2024 Results on May 22, 2024

Gland Pharma Limited Approves Appointment of Mr. Satnam Singh Loomba as Chief Operating Officer, Effective May 1 ,2024

Nicomac Machinery and RP Advisory Services Reportedly Likely to Sell 4.4% Stake in Gland Pharma via Block Deals

Chief Technical Officer recently sold ₹14m worth of stock

Is Gland Pharma (NSE:GLAND) A Risky Investment?

Chief Operating Officer recently sold ₹2.8m worth of stock

Consensus EPS estimates fall by 11%, revenue upgraded

Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q3, 2024 Results on Feb 14, 2024

Chief Technical Officer recently sold ₹27m worth of stock

Chief Technical Officer recently sold ₹27m worth of stock

New minor risk - Insider selling

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q2, 2024 Results on Nov 06, 2023

Chief Technical Officer recently sold ₹10m worth of stock

Gland Pharma Limited Appoints Ankit Gupta as Vice-President (Strategy & Investments)

Investor sentiment improves as stock rises 23%

Gland Pharma Limited Appoints Prakash Vithal Baliga as Chief Operating Officer

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Gland Pharma Limited to Report Q1, 2024 Results on Aug 07, 2023

Investor sentiment deteriorates as stock falls 31%

Price target decreased by 12% to ₹1,520

Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher

Gland Pharma Limited, Annual General Meeting, Aug 31, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insider recently sold ₹1.3m worth of stock

Insider recently sold ₹683k worth of stock

Investor sentiment improves as stock rises 16%

Insider recently sold ₹756k worth of stock

Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value

Price target decreased by 13% to ₹2,119

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Gland Pharma Limited to Report Q3, 2023 Results on Jan 23, 2023

Insider recently sold ₹798k worth of stock

Insider recently sold ₹869k worth of stock

Fosun Reportedly Planning Sale of Gland Pharma

China's Fosun Reportedly Said to Mull Sale of India's $3.6 Billion Gland Pharma

Investor sentiment deteriorated over the past week

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q2, 2023 Results on Oct 26, 2022

Insider recently sold ₹4.1m worth of stock

Insider recently sold ₹2.3m worth of stock

Gland Pharma Limited Announces Xiaohui Guan and Yifang Wu Not Offer for Reappointment as Directors

Insider recently sold ₹1.6m worth of stock